Authors:
BOEHM JC
SMIETANA JM
SORENSON ME
GARIGIPATI RS
GALLAGHER TF
SHELDRAKE PL
BRADBEER J
BADGER AM
LAYDON JT
LEE JC
HILLEGASS LM
GRISWOLD DE
BRETON JJ
CHABOTFLETCHER MC
ADAMS JL
Citation: Jc. Boehm et al., 1-SUBSTITUTED 4-ARYL-5-PYRIDINYLIMIDAZOLES - A NEW CLASS OF CYTOKINE SUPPRESSIVE DRUGS WITH LOW 5-LIPOXYGENASE AND CYCLOOXYGENASE INHIBITORY POTENCY, Journal of medicinal chemistry, 39(20), 1996, pp. 3929-3937
Authors:
BARONE FC
HILLEGASS LM
TZIMAS MN
SCHMIDT DB
FOLEY JJ
WHITE RF
PRICE WJ
FEUERSTEIN GZ
CLARK RK
GRISWOLD DE
SARAU HM
Citation: Fc. Barone et al., TIME-RELATED CHANGES IN MYELOPEROXIDASE ACTIVITY AND LEUKOTRIENE B-4 RECEPTOR-BINDING REFLECT LEUKOCYTE INFLUX IN CEREBRAL FOCAL STROKE, Molecular and chemical neuropathology, 24(1), 1995, pp. 13-30
Authors:
RABINOVICI R
BUGELSKI PJ
ESSER KM
HILLEGASS LM
VERNICK J
FEUERSTEIN G
Citation: R. Rabinovici et al., ARDS-LIKE LUNG INJURY PRODUCED BY ENDOTOXIN IN PLATELET-ACTIVATING FACTOR-PRIMED RATS, Journal of applied physiology, 74(4), 1993, pp. 1791-1802
Authors:
GRISWOLD DE
HILLEGASS LM
BRETON JJ
ESSER KM
ADAMS JL
Citation: De. Griswold et al., DIFFERENTIATION IN-VIVO OF CLASSICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS FROM CYTOKINE SUPPRESSIVE ANTIINFLAMMATORY DRUGS AND OTHER PHARMACOLOGICAL CLASSES USING MOUSE-TUMOR NECROSIS FACTOR-ALPHA PRODUCTION, Drugs under experimental and clinical research, 19(6), 1993, pp. 243-248
Citation: De. Griswold et al., PHARMACOLOGICAL EVALUATION OF LEUKOTRIENE BIOSYNTHESIS AND INFLAMMATION IN AN ADOPTIVE MODEL OF PERITONEAL ANAPHYLAXIS IN THE MOUSE, Drug development research, 30(2), 1993, pp. 83-90
Authors:
RABINOVICI R
BUGELSKI PJ
ESSER KM
HILLEGASS LM
GRISWOLD DE
VERNICK J
FEUERSTEIN G
Citation: R. Rabinovici et al., TUMOR-NECROSIS-FACTOR-ALPHA MEDIATES ENDOTOXIN-INDUCED LUNG INJURY INPLATELET-ACTIVATING FACTOR-PRIMED RATS, The Journal of pharmacology and experimental therapeutics, 267(3), 1993, pp. 1550-1557
Authors:
SMITH EF
GRISWOLD DE
EGAN JW
HILLEGASS LM
SMITH RAG
HIBBS MJ
GAGNON RC
Citation: Ef. Smith et al., REDUCTION OF MYOCARDIAL REPERFUSION INJURY WITH HUMAN SOLUBLE COMPLEMENT RECEPTOR TYPE-1 (BRL-55730), European journal of pharmacology, 236(3), 1993, pp. 477-481